Sanofi to collaborate with Mass General on cancer drug development; Foundation Medicine inks development past with Eisai;

 @FierceBiotech: Fight against 'unwarranted' drug patents goes online. FierceBiotechIT article | Follow @FierceBiotech

 @JohnCFierce: Interesting. Twitter conclusion: Solanezumab a complete bust. But on BMBG, Reuters etc., it's an intriguing "win" for patients. Disconnect. | Follow @JohnCFierce

 @RyanMFierce: Magic Johnson is using his celebrity to bring attention to OraSure's at-home HIV test. A good use of his celebrity, I think.  | Follow @RyanMFierce

> Investigators from Sanofi ($SNY) and Massachusetts General Hospital in Boston will collaborate on a translational medicine project for new cancer therapies. The two-year pact brings together academic and industry professional in preclinical and clinical development work. Sanofi's global oncology group is based in Cambridge, MA. Release

> The 2012 Fierce 15 biotech Foundation Medicine has signed on Eisai to one of its multi-year collaborations on selecting cancer patients for drug studies. This is the latest in a series of pacts with drug developers. Release

> The Danish biotech Veloxis Pharmaceuticals has inked a $47.7 million distribution pact with Italy's Chiesi. Story

Pharma News

@FiercePharma: Scotland rejects Avastin for ovarian cancer. Roche says the Scots need a cancer-drugs fund like England's. Report | Follow @FiercePharma

> J&J eyes new Doxil process to reverse shortage. Story

> Roche: Scotland needs funding for rejected cancer meds. Article

> Merck plots HQ move to former Schering site. More

Medical Device News

 @FierceMedDev: AngioDynamics has agreed to purchase Vortex Medical for $55M. News | Follow @FierceMedDev

 @MarkHFierce: Stem cells derived from skin to be tested in humans as eye disease treatment--via Bloomberg. Article | Follow @MarkHFierce

 @DamianFierce: Boston Scientific will pay up to $265M for Rhythmia Medical. News | Follow @DamianFierce

> Edwards plunges on the Street as sales come up short. News

> Accutron recalls flowmeters over gas risk. Item

Pharma Manufacturing News

> Compounder tied to meningitis deaths sold large quantities. News

> Sanofi Pasteur reports more issues with vaccine quality. Story

> Mold found in Hospira dextrose solution. Report

Biotech Research News

> Japanese scientists weld stem cells to create eggs and then baby mice. More

> RXi gains SBIR grant to pursue RNAi eye cancer drug. News

> Athersys stem cell therapy displays power as MS treatment. Article

> Inovio preclinical results prove skin delivery potency for DNA vaccines. Story

And Finally… A new study indicates that lycopene, an antioxidant found in tomatoes, is associated with a significantly lower risk of stroke among men. The study tracked more than 1,000 Finnish men for more than 12 years. Story

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.